Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Cyclophosphamide; Paclitaxel
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Triple-B
- 20 Aug 2019 Planned End Date changed from 1 Dec 2029 to 1 Dec 2030.
- 20 Aug 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 31 Aug 2018 Biomarkers information updated